# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst David Amsellem reiterates Revance Therapeutics (NASDAQ:RVNC) with a Overweight and lowers the price ta...
Mizuho analyst Vamil Divan maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price target from $9 t...
Needham analyst Serge Belanger maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price target from $18 ...
With cash, cash equivalents, and short-term investments of $277.1 million as of March 31, 2024, and anticipated revenues and ex...
Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of ...
– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN t...